AST was performed simultaneously with the BD Phoenix M50 automated system using NMIC/ID-431 combination panels according to the manufacturer’s instructions. The AST panels have 84 wells with dried antimicrobial agents and 1 growth control well. Principally, the system is a broth-based micro-dilution using a redox indicator solution for the detection of testing bacterial growth in the existence of an antimicrobial agent.9 ,10 Side by side, once the organism identification is done, the MIC values of each antibiotic are generated and interpreted as Susceptible, Intermediate, or Resistant based on the most recent CLSI M100 performance standard guideline for possible phenotypes for microorganism antimicrobial agent combination with the internal database.7 ,9
NMIC/ID-431 panels are intended for use with the BD Phoenix M50 automated system to determine the susceptibility of the clinically relevant aerobic gram-negative rod to the antimicrobial agents; in addition, it indicates resistance markers like carbapenemase. NMIC/ID-431 panels are composed of all recommended antimicrobial agents for P. aeruginosa such as amikacin, cefepime, ceftazidime, ceftolozane-tazobactam, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin-tazobactam, and other intrinsically resistant antimicrobials.7 ,9
NMIC/ID-431 panels are intended for use with the BD Phoenix M50 automated system to determine the susceptibility of the clinically relevant aerobic gram-negative rod to the antimicrobial agents; in addition, it indicates resistance markers like carbapenemase. NMIC/ID-431 panels are composed of all recommended antimicrobial agents for P. aeruginosa such as amikacin, cefepime, ceftazidime, ceftolozane-tazobactam, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin-tazobactam, and other intrinsically resistant antimicrobials.7 ,9